However, according to the findings of a recently published dose–response meta-analysis providing a comprehensive overview of the association between circulating Lp(a) and all-cause and cause-specific mortality, the risk of death from ASCVD increases by 31% for each 50 mg/dL rise in Lp(a) plasma levels [33]. Here, LPA is linked to atherosclerosis.